BioScreening - organic compounds for screening

30.06.2003 June 2003 News Archive

6/30/2003 - Discovery Partners International
Announced that its Swiss affiliate has entered into an assay development and biological screening collaboration with Seikagaku Corporation on an undisclosed target.

6/26/2003 - Fisher Scientific
Fisher Scientific to Buy Perbio Science for $714 Million.

6/25/2003 - Evotec OAI
Evotec OAI and Axxima Pharmaceuticals AG announced a medicinal chemistry agreement to design and synthesis small molecule lead structures for one of Axxima's leading kinase targets. Under the agreement Evotec OAI will apply its integrated medicinal chemistry platform to optimize initial screening hits already identified by Axxima towards candidates for clinical trials.

6/24/03 - Caliper Technologies
Caliper Technologies Announced that Aventis, has purchased the Caliper 250 drug discovery system to develop a series of kinase screening assays using existing LabChip® applications with the potential to develop customized assays and chips. The Caliper 250 system is an integrated, automated drug discovery platform based on Caliper's proprietary microfluidic LabChip technology.

6/18/03 - GlaxoSmithKline
Eyes Robotics to Hasten Drug Discovery. Believes robotics can help succeed where the industry's men in white coats are struggling by installing new robotics technology at a plant near Madrid, Spain. Will vastly increase the number of drugs it can screen against several diseases simultaneously.

6/18/03 - Genedata AG and Novartis Institutes for BioMedical Research
Significantly Expand Functional Genomics Collaboration in Anti-infectives Research. Genedata, a specialist for scientifically validated software systems, will provide NIBR with a license to PathoLead, a specialized computational solution for anti-infective drug discovery, and consulting services.

6/16/2003 - Avantium Technologies BV
Avantium Technologies BV has developed a technology for the rapid optimization of product purification. The technology, Avantium’s Crystallization Screening System (CRYSS), is offered as a contract research service to the pharmaceutical, biotech and fine-chemical industry. CRYSS was developed in response to the pharmaceutical industry’s need for the fast, cost efficient removal of impurities during the manufacture of intermediates or product.

6/11/03 - Argenta Discovery Ltd
Signs Lead Optimisation Deal With Teijin Pharmaceutical Co. Will exploit a range of approaches to deliver an optimised lead series against a cardiovascular disease target.

6/9/03 - Caliper Technologies Corp
ANNOUNCES ACQUISITION OF ZYMARK CORPORATION. Strengthens and Expands Commercial Infrastructure For Microfluidic and Laboratory Automation Products.

new | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003